Defeat mutant KRAS with synthetic lethality.

Area of Science:

• Oncology
• Molecular Biology
• Cancer Genetics

Background:

• Ras proteins are key regulators of fundamental cellular functions.
• Mutated RAS genes are prevalent in human cancers, posing significant therapeutic challenges.
• Targeting Ras signaling remains a critical goal in cancer research, often referred to as "the Everest of oncogenes".

Purpose of the Study:

• To explore novel therapeutic strategies for KRAS-mutant cancers.
• To investigate the potential of targeting synthetic lethal interactors of mutant Ras.
• To evaluate the efficacy of combined inhibition of polo-like kinase 1 (Plk1) and RhoA/Rho kinase (ROCK) in preclinical cancer models.

Main Methods:

• Employed a synthetic lethal drug screen combined with a panel of clinical agents.
• Utilized a combinatorial strategy to identify vulnerabilities in KRAS-mutant cancers.
• Tested the combined regimen of BI-2536 (Plk1 inhibitor) and fasudil (ROCK inhibitor) in patient-derived lung cancer xenografts and LSL-KRAS^G12D mice.

Main Results:

• Discovered that KRAS-mutant cancers are sensitive to the combined inhibition of Plk1 and ROCK.
• The combination of BI-2536 and fasudil significantly inhibited patient-derived lung cancer xenografts.
• The combined regimen prolonged survival in LSL-KRAS^G12D mice, demonstrating therapeutic potential.

Conclusions:

• Combined inhibition of Plk1 and ROCK represents a promising synthetic lethal strategy for KRAS-mutant cancers.
• This approach offers a new avenue for targeting previously undruggable Ras proteins.
• Further development of this combinatorial therapy holds potential for improving outcomes in patients with KRAS-mutant cancers.